Schäfer Ulrich
Department of General and Interventional Cardiology, University Hospital Eppendorf, Hamburg, Germany.
Interv Cardiol. 2017 Sep;12(2):128-132. doi: 10.15420/icr.2017:19:2.
Stroke is a well-documented potential risk of structural cardiac interventions. As a result of the far-reaching burden of stroke on patients, caregivers and the healthcare system, new medical interventions and therapies are being developed to help mitigate this risk. One such intervention is the recently FDA-cleared Sentinel™ Cerebral Protection System (Sentinel; Claret Medical, Santa Rosa, CA, USA) designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures. In the SENTINEL IDE Study, and in a more recent all-comers trial, Sentinel significantly reduced periprocedural strokes by 63 and 70 % respectively. In this paper, we review the growing body of evidence supporting the use of Sentinel in transcatheter aortic valve replacement and other endovascular procedures.
中风是心脏结构介入手术中一个有充分文献记载的潜在风险。由于中风给患者、护理人员和医疗系统带来了深远的负担，新的医学干预措施和疗法正在不断研发，以帮助降低这种风险。其中一种干预措施是最近获得美国食品药品监督管理局（FDA）批准的Sentinel™脑保护系统（Sentinel；Claret Medical，美国加利福尼亚州圣罗莎），该系统旨在捕获和清除经导管主动脉瓣置换手术过程中脱落的碎片。在SENTINEL IDE研究以及最近的一项针对所有患者的试验中，Sentinel分别使围手术期中风显著减少了63%和70%。在本文中，我们回顾了越来越多支持在经导管主动脉瓣置换术和其他血管内手术中使用Sentinel的证据。
